FDA Opens Drug-Approval Pilot While Montana Expands Experimental — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA opened applications for a pilot program first announced in June under Operation TrialBlazer, an HHS initiative pledging to shorten drug approval timelines and help the U.S. compete with biotech industries accelerating in China and Australia.
- The pilot seeks to create a network of "qualified research institutions" that will partner with drugmakers to develop and review Investigational New Drug application packages to get products into human testing faster.
- Libertarian biotech investors helped draft a Montana state law last year expanding access to experimental drugs that no regulator has deemed safe and effective, per Politico.
- Montana now relies on a privately run board to decide which experimental treatments to offer, raising concerns about conflicts of interest and whether patients receive value for their money.
- The company managing Montana's program works with biotech firms in a regulatory-free zone off the coast of Honduras, and startup firms hope Montana will serve as a shortcut around the FDA's costly and extensive drug development process.
Why it matters: Two parallel tracks are emerging: the FDA is accelerating approval timelines through institutional partnerships, while libertarian investors are building a state-level route to bypass federal oversight entirely. Montana's privately run board deciding which unapproved treatments patients can access introduces a new regulatory model that could either pressure the FDA to move faster or create safety gaps if conflicts of interest go unchecked.
Ask SkimNews
